Key result
IV nicorandil is linked to a ~10% shorter sinus cycle length, demonstrating no negative chronotropic effect.
Why the study?
Does IV nicorandil affect cardiac conduction and electrophysiologic parameters in patients with arrhythmias or conduction disorders?
Population
20 patients with sick sinus syndrome (n=8), AV block (n=5), and paroxysmal supraventricular tachycardia (n=7)
Design
Case_series
Authors
Loading...
IV nicorandil lacked negative chronotropic effects in this small series; leaves open its safety and antiarrhythmic utility in conduction disorders.
Observational (n=20)
No
Does IV nicorandil affect cardiac conduction and electrophysiologic parameters in patients with arrhythmias or conduction disorders?
Absolute Event Rate: 819.8% vs 914.8%
p-value: p=<0.01
Nicorandil can be safely used in patients with coronary artery disease and concurrent sick sinus syndrome or AV block, as it lacks negative chronotropic effects and may be effective for intraatrial reentrant tachycardia.
Kanou et al. (1986) conducted an observational in Sick sinus syndrome, AV block, and paroxysmal supraventricular tachycardia (n=20). Nicorandil vs. Baseline was evaluated on Sinus cycle length (msec) (p=<0.01). Intravenous nicorandil (4 mg) significantly shortened sinus cycle length from 914.8 to 819.8 msec and sinus recovery time from 1375.1 to 1284.3 msec, demonstrating no negative chronotropic effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: